We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
Read MoreHide Full Article
United Therapeutics (UTHR - Free Report) reported $748.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 22.9%. EPS of $6.39 for the same period compares to $5.38 a year ago.
The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $717.49 million. With the consensus EPS estimate being $6.18, the EPS surprise was +3.40%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Rest-of-World: $31.60 million versus $30.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +27.4% change.
Revenues- United States: $717.30 million versus the two-analyst average estimate of $654.41 million. The reported number represents a year-over-year change of +22.7%.
Revenues- Remodulin: $128.30 million compared to the $140.21 million average estimate based on seven analysts. The reported number represents a change of -2.1% year over year.
Revenues- Adcirca: $7 million compared to the $5.38 million average estimate based on seven analysts. The reported number represents a change of -4.1% year over year.
Revenues- Unituxin: $61.10 million versus the seven-analyst average estimate of $54.14 million. The reported number represents a year-over-year change of +19.1%.
Revenues- Tyvaso: $433.80 million compared to the $409.89 million average estimate based on seven analysts. The reported number represents a change of +33.2% year over year.
Revenues- Orenitram: $113.20 million versus the seven-analyst average estimate of $106.50 million. The reported number represents a year-over-year change of +23%.
Revenues- Other products: $5.50 million versus $3.10 million estimated by three analysts on average.
Revenue- Nebulized Tyvaso: $159.20 million versus $138.60 million estimated by three analysts on average.
Revenue- Tyvaso DPI: $274.60 million versus the three-analyst average estimate of $263.46 million.
Shares of United Therapeutics have returned -1.4% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
United Therapeutics (UTHR - Free Report) reported $748.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 22.9%. EPS of $6.39 for the same period compares to $5.38 a year ago.
The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $717.49 million. With the consensus EPS estimate being $6.18, the EPS surprise was +3.40%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how United Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Rest-of-World: $31.60 million versus $30.17 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +27.4% change.
- Revenues- United States: $717.30 million versus the two-analyst average estimate of $654.41 million. The reported number represents a year-over-year change of +22.7%.
- Revenues- Remodulin: $128.30 million compared to the $140.21 million average estimate based on seven analysts. The reported number represents a change of -2.1% year over year.
- Revenues- Adcirca: $7 million compared to the $5.38 million average estimate based on seven analysts. The reported number represents a change of -4.1% year over year.
- Revenues- Unituxin: $61.10 million versus the seven-analyst average estimate of $54.14 million. The reported number represents a year-over-year change of +19.1%.
- Revenues- Tyvaso: $433.80 million compared to the $409.89 million average estimate based on seven analysts. The reported number represents a change of +33.2% year over year.
- Revenues- Orenitram: $113.20 million versus the seven-analyst average estimate of $106.50 million. The reported number represents a year-over-year change of +23%.
- Revenues- Other products: $5.50 million versus $3.10 million estimated by three analysts on average.
- Revenue- Nebulized Tyvaso: $159.20 million versus $138.60 million estimated by three analysts on average.
- Revenue- Tyvaso DPI: $274.60 million versus the three-analyst average estimate of $263.46 million.
View all Key Company Metrics for United Therapeutics here>>>Shares of United Therapeutics have returned -1.4% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.